Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews

Abstract Objective:To determine how patients with lung cancer value the trade off between the survival benefit of chemotherapy and its toxicities. Design:Scripted interviews that included three hypothetical scenarios. Each scenario described the same patient with metastatic non-small cell lung cancer with an expected survival of 4 months without treatment. Subjects were asked to indicate the minimum survival benefit required to accept the side effects of chemotherapy in the first two scenarios (mild toxicity and severe toxicity). In the third scenario, subjects were asked to choose between chemotherapy and supportive care when the benefit of chemotherapy was either to prolong life by 3 months or to palliate symptoms. Subjects:81 patients previously treated with cis-platinum based chemotherapy for advanced non-small cell lung cancer. Main outcome measure:Survival threshold for accepting chemotherapy. Results:The minimum survival threshold for accepting the toxicity of chemotherapy varied widely in patients. Several patients would accept chemotherapy for a survival benefit of 1 week, while others would not choose chemotherapy even for a survival benefit of 24 months. The median survival threshold for accepting chemotherapy was 4.5 months for mild toxicity and 9 months for severe toxicity. When given the choice between supportive care and chemotherapy only 18 (22%) patients chose chemotherapy for a survival benefit of 3 months; 55 (68%) patients chose chemotherapy if it substantially reduced symptoms without prolonging life. Conclusions:Patients' willingness to accept chemotherapy for the treatment of metastatic lung cancer varies widely. Many would not choose chemotherapy for its likely survival benefit of 3 months but would if it improved quality of life. The conflict between these patients' preferences and the care they previously received has several explanations, one being that some patients had not received the treatment they would have chosen had they been fully informed.

[1]  V. Devita,et al.  Cancer : Principles and Practice of Oncology , 1982 .

[2]  D. Cella,et al.  Age and clinical decision making in oncology patients. , 1994, Journal of the National Cancer Institute.

[3]  A. Tversky,et al.  On the elicitation of preferences for alternative therapies. , 1982, The New England journal of medicine.

[4]  L. Fallowfield,et al.  Offering choice of treatment to patients with cancers. A review based on a symposium held at the 10th annual conference of The British Psychosocial Oncology Group, December 1993. , 1995, European journal of cancer.

[5]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.

[6]  G. Chapman,et al.  [Medical decision making]. , 1976, Lakartidningen.

[7]  F. Invernizzi,et al.  Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature. , 1994, Chest.

[8]  P. Wingo,et al.  Cancer statistics, 1997 , 1997, CA: a cancer journal for clinicians.

[9]  S. Kaasa,et al.  Polychemotherapy in advanced non small cell lung cancer: a meta-analysis , 1993, The Lancet.

[10]  E. Nord,et al.  Methods for quality adjustment of life years. , 1992, Social science & medicine.

[11]  M. Brundage,et al.  Trading treatment toxicity for survival in locally advanced non-small cell lung cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  H. Muss,et al.  Patient preferences for treatment of metastatic breast cancer: a study of women with early-stage breast cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  A. Oxman,et al.  Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough? , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  J P Kassirer,et al.  Incorporating patients' preferences into medical decisions. , 1994, The New England journal of medicine.

[15]  S. Kagamimori,et al.  Working hours as a risk factor for acute myocardial infarction in Japan: case-control study , 1998, BMJ.

[16]  W. Gregory,et al.  Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public. , 1990, BMJ.